Pioneer in evidence-based medicine to create and market products for early
detection and intervention in high-mortality disease states
DEDHAM, Mass., July 20 /PRNewswire/ -- As part of its mission to deliver
safe and efficacious medicines to critical areas of need, Signet Laboratories,
Inc., a pioneer in evidence-based medicine (EviMed), today announced it will
develop and commercialize predictive diagnostics and preventive therapeutics
to combat Sepsis and Acute Renal Failure (S/ARF).
Signet Laboratories will draw on its current successful portfolio of
diagnostic markers and intellectual property in S/ARF, as well as its existing
partnerships in clinical and regulatory development, to bring to market
products for detecting early signs of both Sepsis and Acute Renal Failure, and
rapid treatments to help prevent onset and curb mortality rates.
According to Dr. Richard D. Gill, President and CEO of Signet
Laboratories, "S/ARF are eminently preventable conditions if identified in
time. Unfortunately, to date, clinicians have been dependent on testing
regimes that catch warning signs too late, only after dangerous infectious
insult and renal damage have set in. The need for better tests and drugs to
fight S/ARF is critical, given the high mortality rate of Sepsis (16%), Severe
Sepsis (20%) and Septic Shock (46%), and the 50% or higher mortality rate of
Acute Renal Failure."
He added, "Our ABP-26(TM) and NEPHROSCREEN(TM) RUO diagnostics are already
available for predictive detection of Sepsis and Acute Renal Failure,
respectively, and Signet Laboratories is now in a position to develop drugs to
be used in tandem with these diagnostics to give physicians a better early
warning system and interventive options to stave off mortality and
irreversible damage."
About Signet Laboratories, Inc.
Signet Laboratories, Inc. is a pioneering evidence-based medicine (EviMed)
company that is committed to developing and commercializing predictive
diagnostics and preventive drugs and therapies for critical disease states.
Evidence-based medicine is the treatment of diseases prior to their full
manifestation, with the goal of reducing their occurrence and preventing
disease progression by early identification of patients with increased risk
factors.
Drawing on long experience in developing diagnostic assays and antibodies
for disease detection and treatment, Signet Laboratories' mission is to create
novel diagnostics and drugs for patients at risk for cancer, sepsis and renal
failure (SARF), neurodegenerative diseases including Alzheimer's, Parkinson's
and Huntington's, and prion diseases such as "Mad Cow" and vCJD.
In addition to diagnostics, drugs and therapies, Signet Laboratories
offers a complete product line of over 800 manufactured antibodies, ELISA
kits, detection products and accessories in an FDA registered facility. Signet
Laboratories products are available online, at http://www.signetlabs.com.
For more information, contact Terri Daly at (781) 915-1404, or via email:
tdaly@signetlabs.com.
SOURCE Signet Laboratories, Inc.
 back to top
Related links:
http://www.signetlabs.com
CONTACT:
Terri Daly of Signet Laboratories, Inc.,
+1-781-915-1404, tdaly@signetlabs.com
|
